AbbVie reportedly is in talks to divest the women’s health drugs it acquired last year through its $63 billion Allergan acquisition.
Reuters reports the North Chicago-based drugmaker is looking to sell the roughly $5 billion portfolio, which includes the oral contraceptive Lo Loestrin Fe.
The drugs generate about $500 million in earnings before interest, taxes, depreciation and amortization over 12 months, and they could be valued at about $5 billion, sources told Reuters.
CVC Capital Partners reportedly is interested in buying AbbVie’s women’s health portfolio, Reuters says. The private-equity firm in 2018 acquired Teva Pharmaceutical’s women’s health assets.
Allergan looked to offload the business in 2018, but passed on a sale a year later—months before AbbVie agreed to buy the Irish drugmaker.
AbbVie did not immediately respond to a request for comment.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
